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Matrilin-3 (MATN3) is a skeletal-speciﬁc, tetrameric pericellular
protein1e3, localizing to the pericellular matrix of chondrocytes. It
accumulates in higher amounts in osteoarthritic cartilage in
human4. Indeed, in vitro characterization of MATN3 identiﬁed anti-
anabolic5 and pro-catabolic functions6, although it was also found
to favour chondrogenesis of synovial ﬁbroblasts7. As MATN3 is
virtually speciﬁcally expressed in cartilage, over-expressed upon
osteoarthritis and as its functions may participate in the mecha-
nisms of the disease, it may constitute a useful marker to diagnose
osteoarthritis or to evaluate its progression, not only from synovial
ﬂuids (SF), but also from circulating ﬂuids. However, methods to
quantify MATN3 from complex solutions are lacking. Here, we
report the establishment of a direct, competitive Enzyme-Linked
Immunosorbent Assay (ELISA) method prepared from commer-
cially available antibodies and reagents, which allows reproducible
determination of MATN3 levels in the nanogramm to microgramm
per millilitre range. The method will be useful to conclude whether
MATN3 will be a useful marker to diagnose osteoarthritis and/or to
follow its progression using a non-invasive and ﬁnancially afford-
able technique.o: J-B. Vincourt, UMR 7561
rêt de Haye, BP 184, 54505
; Fax: 33-3-83-68-39-59.
uhp-nancy.fr (J.-B. Vincourt).
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Patients
SF and sera were obtained in the context of total knee
replacement due to end-stage osteoarthritis. Patients gave
written informed consent in accordance with the usual ethical
regulations in collaboration with our local bone bank. This study
was approved by our local Research Institution review board
(registration number UF 9757 - CPRC 2004 - Cellules souches et
chondrogénèse). The average age of patients was 70 years
(ranging from 47 to 88) and 68% of them were females. Their
Kellgren & Lawrence grades ranged from 2 to 4. No correlations
were evidenced between these and MATN3 levels. 20 sera and
15 SFs were collected from 25 patients. From 10 patients,
both serum and SF were used to compareMATN3 levels in both
ﬂuids.Sample collection, conservation and processing
SF samples were collected under general anaesthesia during
total knee replacements. Sera were obtained during pre-operative
procedures. Aliquots were centrifuged at 10,000 g for 5 min and
clariﬁed supernatants were transferred and frozen at 80C. For
measurement, aliquots were thawed on ice and clariﬁed again
using the same centrifugation procedure. Aliquots were not reused
after more than one freeze-thaw cycle.ublished by Elsevier Ltd. All rights reserved.
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Measurements were performed in triplicates unless stated
otherwise. For assay validation, optical density (OD) was ﬁtted
against analyte concentration applying a logarithmic regression to
the calibration curve. Average, standard deviations (SD) and
differences from theoretical values were calculated for all standards
and samples.
Direct, competitive ELISA procedure
In preliminary experiments, only one commercial antibody
(MAB3017 from R&D) achieved sufﬁcient speciﬁcity and sensitivity
to MATN3 in direct ELISA assays (data not shown). Therefore,
a competitive assay was required. The antibody was coated onto
plastic surfaces and then exposed to mixed analyte and labelled
competitor, the binding of the latter being then measured. A frac-
tion of commercial recombinant MATN3 was biotinylated using
Sulfo-NHS biotinylation kit (Pierce) and used as competitor after
dialysis to PBS (Gibco) containing 0.1% azide. Another fraction was
suspended in PBS and serial diluted in FCS for use as standards.
96-well Maxisorp (Nunc) plates were coated with 1 mg/ml antibody
overnight at 4C. Non-speciﬁc binding was blocked with 3% BSA
(type IV BSA, from Euromedex) in PBS for 1 hour. Meanwhile, an
identical concentration of 50 ng/ml competitor MATN3 was added
to each standard or analyte fraction and homogenized. Standards
(500 pg/mle1 mg/ml) were then added to wells and incubated for
3 hours under constant shaking. Wells were washed ﬁve times in
PBS containing 0.2% Tween-20 (PBST), streptavidin-HRP (from
R&D) diluted in 3% BSAwas added for 45 min in 3% BSA andwashed
ﬁve times again in PBST. Detection was performed as speciﬁed by
the manufacturer (R&D) and measurements were performed on
a Multiscan EX (Fisher Thermoscientiﬁc).
Standard curves
Standard curves were prepared using recombinant MATN3
diluted into FCS (FCS reacted insigniﬁcantly to the assay as deter-
mined using BSA as a negative control). Typical results using
standard concentrations ranging from 500 pg/ml to 1 mg/ml
exhibited classical saturation curves with SDs of all values falling
within 10% of the average measure. The standard curves ﬁtted to
logarithmic regressions with sufﬁcient correlation coefﬁcients
throughout this concentration range [Fig. 1(A)], allowing back-A
Fig. 1. Saturation curve and speciﬁcations of the assay. (A) Classically observed dose-respo
regression curve together with the correlation coefﬁcient (r2) are annotated. The plot showscalculation of each concentration from the measured absorbance
with errors lower than 15% compared to theoretical values.Validation on sera and SFs
The assay was applied to 20 sera and 15 SFs obtained from
osteoarthritic patients. Sera (100 ml) were directly used as diluents
for competitors as described for standards. SFs were diluted 10-fold
in FCS containing 55 mg/ml competitor. The range of concentration
measurement using this assay ﬁtted to concentrations found in all
35 samples, which ranged from 80 to 2700 ng/ml. When deter-
mining the recovery by dilution to patient samples [Supplemental
Fig. 1 (A)], all recoveries were within 20% as long as dilutions
fell into a range between 2 ng/ml and 1 mg/ml. This was not a limit
for calculations of MATN3 levels in either ﬂuid, which all fell into
this interval (taking into account that SFs were 10-fold diluted).
In order to further validate the assay, dilutions of standards into
human ﬂuids of previously characterized MATN3 concentrations
were performed and their total concentrations were measured
[Supplemental Fig. 1(B)]. In all tested ﬂuids, measured MATN3
concentrations ﬁtted to theoretical values with errors lower than
15%.
The average intra-assay variability was 6.1% and the average
inter-assay variability was 9.1%.Speciﬁcations of the assay
The numerical values of the speciﬁcations were compiled in
[Fig. 1 (B)]. Recovery rates were calculated after measurements of
up to 64-fold serial dilutions of two samples of each ﬂuid into FCS.
Initial concentrations were back-calculable as long as diluted
concentrations remained higher or equal to 2 ng/ml. Competitions
between samples and standards were performed from two samples
of each ﬂuid in which standards were diluted. The intra-assay and
inter-assay precisions were measured from eight independent runs
of one SF and two serum samples (all samples being prepared
together). The inter-assay precision was determined by eight
independent measurements at eight different days over a 3 weeks
period.
The lower limit of detection [Fig. 1 (B)] was considered as the
lowest concentration that could be measured with a an SD lower
than 10% and that allowed back-calculation using the regression
curvewith an error lower than 15%, from three independent assays.B
nse of the assay represented on a logarithmic concentration scale. The equation of the
average measures and bars indicate SD. (B) summary of the speciﬁcations of the assay.
Fig. 2. Speciﬁcity of the antibody and adaptation of the assay to SFs and sera. (A) Proteomic investigation of the speciﬁcity of the antibody used in the assay. SFs found by ELISA to
contain high versus low MATN3 amounts were subjected to immunoprecpitation using the same antibody and the immunoprecipitates were analyzed by 2D-electrophoresis
coupled mass spectrometry. Spots of interest are indicated by arrows. (B) Comparison of SF and serum contents in Matrilin-3 from 10 patients. Segments link measures of both
compartments for each individual patient. SD were not indicated to allow visualization of details. The indicated p value is as calculated by the student t test.
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In order to address the stability of the reagents after prepara-
tion, test measurements from standards were performed twice at
a 3 months interval all reagents being kept at 4C in triplicates and
exhibited an inter-assay variation of 12%. It is worth noticing that all
reagents can be prepared from stable commercial products within
24 hours.Speciﬁcity of the antibody
We investigated the speciﬁcity of the single antibody used in
this method by immunoprecipitation coupled to 2D-gel electro-
phoresis andmass spectrometry [Fig. 2 (A)].1 ml aliquots of two SFs
of respectively high and low MATN3 concentrations as determined
by ELISA were used in this experiment. 10 mg biotinylated antibody
was added to each sample and incubated overnight. On the next
day, 10 ml neutravidin beads (PIERCE) were added, incubated for
1 hour, rinsed three times in PBST and eluted in PBST containing
100 mMDTT. The eluates were subjected to 2D-electrophoresis and
revealed by Coomassie staining. Spots were identiﬁed by mass
spectrometry of tryptic peptides with high conﬁdence scores.
Several spots were observed on both gels. A few corresponded to
proteins such as serum albumin and alpha-antitrypsin (not shown),
which most likely bound non-speciﬁcally to the beads. Mouse
immunoglobulin chains were also found, as expected [Fig. 2 (A)].
Finally, two spots were observed only from the sample with high
MATN3 content and these two spots were identiﬁed as human
MATN3, verifying that the antibody bound to MATN3 and not at
comparable levels to other SF constituents.Comparison in individual patients of the MATN3 content of SFs and
sera
Because MATN3 is virtually speciﬁc to cartilage, its content
would be presumed to be much higher in SF than serum. However,
markers of cartilage metabolism have previously been found
measurable in serum8. We compared concentrations of MATN3
measured from 10 SFs to those observed in 10 sera originating from
the same 10 patients, respectively [Fig. 2 (B)]. In all cases, SF levels
were higher than serum levels, as intuitively thought. The fold
difference ranged approximately from 2 to 10. The patients who
exhibited highest MATN3 levels in SFs also exhibited the highest
levels in their sera, suggesting that elevated MATN3 in a joint may
be evidenced from its serum levels.All biological ﬂuids used here were obtained from patients
suffering from end-point knee osteoarthritis. As described by
others4, MATN3 levels in osteoarthritic articular cartilage continu-
ously increase throughout progression of the disease. Therefore,
the population used here for assay validation may exhibit partic-
ularly high MATN3 levels. However, a conclusion of our initial
investigations of MATN3 levels in SFs from those patients is that the
release of MATN3 in SF may not be a homogenous hallmark of
osteoarthritis: among 15 patients, the fold difference betweenmost
distant concentrations was almost 50 (data not shown). Future
investigations frommuch larger and better controlled populations8
will determine whether the measurement of MATN3 levels in
serum can be used to predict or follow the evolution of osteoar-
thritis. If so, the assay will be useful as it is achievable from serum,
affordable and technically feasible.
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